mercredi 3 juin 2015

Onco Actu du 3 juin 2015

1. Biologie

Rebooting the Human Genome [MIT Technology Review]

2.6 Etiologie - Environnement

Why I despise Mike Adams: Blaming Beau Biden’s cancer on chemotherapy and glyphosate [Respectful Insolence]

3.1 Tabac

U.S. tobacco companies drop lawsuit vs FDA over labeling [Reuters]

5. Traitements

Mother fights brain cancer with electric fields [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

Juno Therapeutics Adds Antibody Engineering Capabilities Through Acquisition of X-BODY [Juno]

AstraZeneca’s Soriot Open to Buying Immune-Therapy Company [Bloomberg]

5.3 Traitements - FDA, EMA,...

FDA panel to discuss Lilly's lung cancer drug approval [Reuters]

5.5.1 ASCO (général)

Baby, can you drive my CAR-T? Great potential and excitement, but questions remain [The OBR Blog]

ASCO Roundup: Checkpoints, Pushback Against Prices, CAR-T & More [Xconomy]

The Survivors And Advocates Highlight That Personalized Medicine Is About All Of Us [Dr Len]

ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate [Forbes] ASCO (général) - Industriels

With a crucial CAR-T trial looming for Cellectis, a confident André Choulika is laying it all on the line [FierceBiotech] ASCO (général) - Académiques

Illuminating insights and innovative ideas at the world’s largest cancer conference [The Institute of Cancer Research]

5.5.10 ASCO (hémato)

Crowd surfing: Competition in myeloma continues to rage on [The OBR Blog]

Gaga over Gazyva? GADOLIN shows clinical benefit in Rituxan-refractory indolent NHL [The OBR Blog]

Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine [BMS]

5.5.12 ASCO (médico-éco)

Why I won’t be rushing to tell my cancer patients there’s a cure [The Guardian]

5.5.13 ASCO (divers)

NCI Gets Personal [The Scientist]

Statins can halve patients' risk of dying from cancer [The Telegraph]

5.5.2 ASCO (sein)

Study finds misperceptions about impact of double mastectomy [University of Michigan]

5.5.4 ASCO (immunothérapies)

Immunotherapy continues to grow; the question may soon become where this class of agents won’t have a strong impact [The OBR Blog]

Tumor tests for immuno-oncology drugs need some work, cancer experts say [FiercePharma]

5.5.9 ASCO (autres organes)

Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma [Johnson & Johnson]

6.1 Observation

U.S. melanoma rate is now double what it was 30 years ago [LA Times]

6.3 Associations

Rochelle Shoretz, Founder of Cancer Support Group, Dies at 42 [NY Times]

6.6 Publications

NEJM reignites conflict-of-interest debate with reader poll [HealthNewsReview]

6.8 Communication

Oncology hashtag project aims to improve accuracy of online communication about cancer [Scope Blog]